Stachytarpheta Extract Composition for Vitiligo Repigmentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for vitiligo are not satisfactory in terms of efficacy and safety, and the production of extracts from Stachytarpheta polyura, a species used in prior art, is unfeasible and costly due to rarity and small size.

Innovation Solution

Development of pharmaceutical compositions using standardized extracts or isolated compounds from Stachytarpheta cayennensis, S. jamaicensis, and S. eliotis, which are more abundant and easier to produce, combined with natural or synthetic products, for oral and topical administration to treat vitiligo.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If extracts are produced from Stachytarpheta polyura as used in prior art, then therapeutic effect for vitiligo is achieved, but production becomes unfeasible and costly due to rarity and small size of the plant

Engineering Contradiction:

Improvetherapeutic effectVSAvoidproduction feasibility

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent substitutes the rare Stachytarpheta polyura with abundant Stachytarpheta cayennensis that replicates the same therapeutic properties. This copying approach maintains the therapeutic effect while eliminating production difficulties associated with the original rare plant species.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent employs readily available Stachytarpheta cayennensis plants that can be easily cultivated and harvested, replacing the expensive and difficult-to-obtain S. polyura. This substitution makes the extract production economically viable and scalable.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If existing treatments for vitiligo are used, then treatment is provided, but efficacy and safety are not satisfactory

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical composition parameter by using extracts from S. cayennensis containing specific compounds (stachytarphedin, verbascoside, rosmarinic acid) that provide therapeutic efficacy with improved safety profile compared to existing treatments, thereby optimizing the efficacy-toxicity ratio.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If standardized extracts from Stachytarpheta cayennensis are used, then repigmentation effect is achieved with over 50% of patients showing improvement, but requires long treatment period of 18 months

Engineering Contradiction:

Improverepigmentation effectVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent employs standardized extracts with predetermined active compound concentrations that prepare the skin for repigmentation from the outset, establishing a foundation for gradual melanocyte restoration throughout the 18-month treatment period, thereby maximizing the repigmentation effect over time.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12514896B2Pharmaceutical composition on the basis of <i>stachytarpheta </i>sp., a process for obtaining the same and its use for treating vitiligo

Publication Date: 2026.01.06 ACHE LAB FARM

AI summary

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plant of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.